Lv3
210 积分 2023-04-06 加入
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
1个月前
已完结
Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of N-Acetylgalactosamine–Conjugated Small Interfering RNA Disposition and Gene Silencing in Preclinical Species and Humans
1个月前
已关闭
Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of N-Acetylgalactosamine–Conjugated Small Interfering RNA Disposition and Gene Silencing in Preclinical Species and Humans
1个月前
已完结
Prediction of Interspecies Translation for Targeting Delivery Coefficients of GalNAc-siRNA Silencing Apolipoprotein C-III Using a Mechanistic Minimal Physiologically Based Pharmacokinetic/Pharmacodynamic Model
1个月前
已完结
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial
1个月前
已完结
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
4个月前
已完结
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
4个月前
已完结
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
5个月前
已完结
A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation
7个月前
已完结
A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation
7个月前
已完结
皖公网安备34019202002308
